Data

ASPREE Genome-wide SNP Genotyping Dataset

Monash University
John McNeill (Aggregated by) Paul Lacaze (Aggregated by)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26180/21097654.v1&rft.title=ASPREE Genome-wide SNP Genotyping Dataset&rft.identifier=https://doi.org/10.26180/21097654.v1&rft.publisher=Monash University&rft.description=ASPirin in Reducing Events in the Elderly (ASPREE) is a clinical trial and longitudinal study of healthy ageing, involving 16,703 Australians aged over 70 years and 2,411 Americans aged over 65 enrolled. The primary ASPREE trial has received >$60M in NIH funding since 2012. Each ASPREE participants’ health is tracked longitudinally through extensive phenotyping and collection of clinical outcome data. The ASPREE Healthy Ageing Biobank is an associated biorepository of blood, saliva and urine samples from >15,000 ASPREE participants, 10,000 of whom have now provided a matched follow-up 3-year sample. Biospecimens are consented for genetic and biomarker studies, enabling ASPREE to conduct molecular epidemiology and healthy ageing research. ASPREE facilitates over 12 sub-studies funded through NHMRC. Genome wide association analysis has been undertaken in multiple areas: All-cause and vascular dementia Stroke Genetic modifiers for Alzheimer's disease Poygenic resilence scores capture genetic effect for Alzheimers disease Genome wide association analysis for Alzheimers Disease https://bioplatforms.com/projects/aspree-framework-initiative/ To make data requests, you may undertake an approval process by contacting Paul Lacaze on Paul.Lacaze@monash.edu &rft.creator=John McNeill&rft.creator=Paul Lacaze&rft.date=2022&rft_rights=CC-BY-4.0&rft_subject=ARDC Data Retention Project&rft.type=dataset&rft.language=English Access the data

Licence & Rights:

Open Licence view details
CC-BY

CC-BY-4.0

Full description

ASPirin in Reducing Events in the Elderly (ASPREE) is a clinical trial and longitudinal study of healthy ageing, involving 16,703 Australians aged over 70 years and 2,411 Americans aged over 65 enrolled. The primary ASPREE trial has received >$60M in NIH funding since 2012. Each ASPREE participants’ health is tracked longitudinally through extensive phenotyping and collection of clinical outcome data. The ASPREE Healthy Ageing Biobank is an associated biorepository of blood, saliva and urine samples from >15,000 ASPREE participants, 10,000 of whom have now provided a matched follow-up 3-year sample. Biospecimens are consented for genetic and biomarker studies, enabling ASPREE to conduct molecular epidemiology and healthy ageing research. ASPREE facilitates over 12 sub-studies funded through NHMRC.

Genome wide association analysis has been undertaken in multiple areas:

  • All-cause and vascular dementia
  • Stroke
  • Genetic modifiers for Alzheimer's disease
  • Poygenic resilence scores capture genetic effect for Alzheimers disease
  • Genome wide association analysis for Alzheimers Disease

https://bioplatforms.com/projects/aspree-framework-initiative/

To make data requests, you may undertake an approval process by contacting Paul Lacaze on Paul.Lacaze@monash.edu



Issued: 2022-10-18

Created: 2022-10-18

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover